List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3428031/publications.pdf Version: 2024-02-01

		31902	21474
217	14,080	53	114
papers	citations	h-index	g-index
221	221	221	6623
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Comparative Outcomes of Cap Assisted Endoscopic Resection and Endoscopic Submucosal Dissection in Dysplastic Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2022, 20, 65-73.e1.	2.4	22
2	Diagnostic performance of volumetric laser endomicroscopy for Barrett's esophagus dysplasia amongst gastroenterology trainees. Translational Gastroenterology and Hepatology, 2022, 7, 0-0.	1.5	0
3	Feasibility and Safety of Tethered Capsule Endomicroscopy in Patients With Barrett's Esophagus in a Multi-Center Study. Clinical Gastroenterology and Hepatology, 2022, 20, 756-765.e3.	2.4	15
4	Endoscopic submucosal dissection and potential cancer dissemination. Gut, 2022, 71, 236-237.	6.1	2
5	Spray cryotherapy prevents need for palliative stenting in patients with esophageal cancer-associated dysphagia. Ecological Management and Restoration, 2022, 35, .	0.2	8
6	Wide-area transepithelial sampling for dysplasia detection in Barrett's esophagus: a systematic review and meta-analysis. Gastrointestinal Endoscopy, 2022, 95, 51-59.e7.	0.5	21
7	Comparative outcomes of radiofrequency ablation and cryoballoon ablation in dysplastic Barrett's esophagus: a propensity scoreâ^'matched cohort study. Gastrointestinal Endoscopy, 2022, 95, 422-431.e2.	0.5	13
8	Limitations of Heartburn and Other Societies' Criteria in Barrett's Screening for Detecting De Novo Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2022, 20, 1709-1718.	2.4	17
9	Spray cryotherapy versus continued radiofrequency ablation in persistent Barrett's esophagus. Ecological Management and Restoration, 2022, , .	0.2	2
10	Optimized Surveillance Intervals Following Endoscopic Eradication of Dysplastic Barrett's Esophagus: An International Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, 2763-2771.e3.	2.4	4
11	Rio de Janeiro Global Consensus on Landmarks, Definitions, and Classifications in Barrett's Esophagus: World Endoscopy Organization Delphi Study. Gastroenterology, 2022, 163, 84-96.e2.	0.6	6
12	Clinical significance of recurrent gastroesophageal junction intestinal metaplasia after endoscopic eradication of Barrett's esophagus. Gastrointestinal Endoscopy, 2021, 93, 1250-1257.e3.	0.5	12
13	Neoplasia Detection Rate in Barrett's Esophagus and Its Impact on Missed Dysplasia: Results from a Large Population-Based Database. Clinical Gastroenterology and Hepatology, 2021, 19, 922-929.e1.	2.4	20
14	Outcomes of radiofrequency ablation by manual versus self-sizing circumferential balloon catheters for the treatment of dysplastic Barrett's esophagus: a multicenter comparative cohort study. Gastrointestinal Endoscopy, 2021, 93, 880-887.e1.	0.5	4
15	Application of artificial intelligence using a novel EUS-based convolutional neural network model to identify and distinguish benign and malignant hepatic masses. Gastrointestinal Endoscopy, 2021, 93, 1121-1130.e1.	O.5	22
16	Safety and feasibility of same-day discharge after esophageal endoscopic submucosal dissection. Gastrointestinal Endoscopy, 2021, 93, 853-860.	0.5	12
17	Epidemiology and Outcomes of Young-Onset Esophageal Adenocarcinoma: An Analysis from a Population-Based Database. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 142-149.	1.1	40
18	Expert assessment on volumetric laser endomicroscopy full scans in Barrett's esophagus patients with or without high grade dysplasia or early cancer. Endoscopy, 2021, 53, 218-225.	1.0	4

#	Article	IF	CITATIONS
19	Longitudinal and Circumferential Distributions of Dysplasia and Early Neoplasia in Barrett's Esophagus: A Pooled Analysis of Three Prospective Studies. Clinical and Translational Gastroenterology, 2021, 12, e00311.	1.3	2
20	Esophageal Epidermoid Metaplasia: Clinical Characteristics and Risk of Esophageal Squamous Neoplasia. American Journal of Gastroenterology, 2021, 116, 1533-1536.	0.2	10
21	External validation of blue light imaging (BLI) criteria for the optical characterization of colorectal polyps by endoscopy experts. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2728-2734.	1.4	8
22	Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening. American Journal of Gastroenterology, 2021, 116, 1620-1631.	0.2	18
23	EUS-guided verteporfin photodynamic therapy for pancreatic cancer. Gastrointestinal Endoscopy, 2021, 94, 179-186.	0.5	39
24	Scissor-type knife improves the safety of endoscopic submucosal dissection (ESD) among endoscopists without experience in ESD: a randomized ex vivo study. Endoscopy International Open, 2021, 09, E1207-E1213.	0.9	1
25	Impact of bariatric surgery on surveillance and treatment outcomes of Barrett's esophagus: A stage-matched cohort study. Surgery for Obesity and Related Diseases, 2021, 17, 1457-1464.	1.0	5
26	CT radiomic features of photodynamic priming in clinical pancreatic adenocarcinoma treatment. Physics in Medicine and Biology, 2021, 66, 175006.	1.6	12
27	Photodynamic priming with triple-receptor targeted nanoconjugates that trigger T cell-mediated immune responses in a 3D <i>in vitro</i> heterocellular model of pancreatic cancer. Nanophotonics, 2021, 10, 3199-3214.	2.9	12
28	Validation of a methylated DNA marker panel for the nonendoscopic detection of Barrett's esophagus in a multisite case-control study. Gastrointestinal Endoscopy, 2021, 94, 498-505.	0.5	17
29	Inhibition of the BMP pathway prevents development of Barrett's-associated adenocarcinoma in a surgical rat model. Ecological Management and Restoration, 2021, , .	0.2	0
30	Risk Factor Profiles Can Distinguish Esophageal Adenocarcinoma From Barrett's Esophagus. American Journal of Gastroenterology, 2021, 116, 198-201.	0.2	3
31	Dramatic Reduction of Distant Pancreatic Metastases Using Local Light Activation of Verteporfin with Nab-Paclitaxel. Cancers, 2021, 13, 5781.	1.7	2
32	Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis. Gastrointestinal Endoscopy, 2020, 91, 3-10.e3.	0.5	36
33	Comparison of Phenotypes and Risk Factors for Esophageal Adenocarcinoma at Present vs Prior Decades. Clinical Gastroenterology and Hepatology, 2020, 18, 2710-2716.e1.	2.4	5
34	Clinical impact of celiac ganglia metastasis upon pancreatic ductal adenocarcinoma. Pancreatology, 2020, 20, 110-115.	0.5	1
35	Photodynamic Therapy for Gastrointestinal Cancer. Photochemistry and Photobiology, 2020, 96, 517-523.	1.3	47
36	Safety and histologic outcomes of endoscopic submucosal dissection with a novel articulating knifeAforAesophageal neoplasia. Gastrointestinal Endoscopy, 2020, 91, 797-805.	0.5	9

#	Article	IF	CITATIONS
37	Finding Barrett's oesophagus: is there a machine learning approach in our future?. The Lancet Digital Health, 2020, 2, e6-e7.	5.9	1
38	Screening for Barrett's oesophagus: is now the time?. Lancet, The, 2020, 396, 292-293.	6.3	0
39	NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer. Journal of Clinical Medicine, 2020, 9, 2390.	1.0	20
40	Accurate Nonendoscopic Detection of Barrett's Esophagus by Methylated DNA Markers: A Multisite Case Control Study. American Journal of Gastroenterology, 2020, 115, 1201-1209.	0.2	28
41	AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Annals of Allergy, Asthma and Immunology, 2020, 124, 416-423.	0.5	41
42	Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. Gastrointestinal Endoscopy, 2020, 92, 31-39.e1.	0.5	33
43	Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma. Gastroenterology, 2020, 159, 575-590.	0.6	49
44	AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology, 2020, 158, 1776-1786.	0.6	188
45	Risk factors for serious adverse events associated with multiband mucosectomy in Barrett's esophagus: an international multicenter analysis of 3827 endoscopic resectionÂprocedures. Gastrointestinal Endoscopy, 2020, 92, 259-268.e2.	0.5	8
46	Gene expression profiles of esophageal squamous cell cancers in Hodgkin lymphoma survivors versus sporadic cases. PLoS ONE, 2020, 15, e0243178.	1.1	2
47	How I Treat Patients With Barrett Esophagus When Endoscopic Ablation Fails. Gastroenterology and Hepatology, 2020, 16, 82-87.	0.2	0
48	Endoscopic Treatment of Early Esophageal Neoplasia. , 2019, , 302-315.e2.		0
49	Accuracy of Endoscopic Ultrasound Imaging in Distinguishing Celiac Ganglia From Celiac Lymph Nodes. Clinical Gastroenterology and Hepatology, 2019, 17, 148-155.e3.	2.4	7
50	Safety, Diagnostic Accuracy, and Effects of Endoscopic Ultrasound Fine-Needle Aspiration on Detection of Extravascular Migratory Metastases. Clinical Gastroenterology and Hepatology, 2019, 17, 2533-2540.e1.	2.4	11
51	AGA Clinical Practice Update on the Utility of Endoscopic Submucosal Dissection in T1b Esophageal Cancer: Expert Review. Clinical Gastroenterology and Hepatology, 2019, 17, 2161-2166.	2.4	15
52	Outcome of endoscopic mucosal resection in Barrett's esophagus determined by systematic quantification of epithelial glands using volumetric laser endomicroscopy. Gastrointestinal Endoscopy, 2019, 89, 701-708.e1.	0.5	6
53	ASGE EndoVators Summit: simulators and the future of endoscopic training. Gastrointestinal Endoscopy, 2019, 90, 13-26.	0.5	27
54	Staging of T1 esophageal adenocarcinoma with volumetric laser endomicroscopy: a feasibility study. Endoscopy International Open, 2019, 07, E462-E470.	0.9	1

#	Article	IF	CITATIONS
55	Persistent intestinal metaplasia after endoscopic eradication therapy of neoplastic Barrett's esophagus increases the risk of dysplasia recurrence: meta-analysis. Gastrointestinal Endoscopy, 2019, 89, 913-925.e6.	0.5	32
56	Esophageal Leukoplakia. ACG Case Reports Journal, 2019, 6, e00213.	0.2	5
57	What Constitutes Optimal Management of T1N0 Esophageal Adenocarcinoma?. Annals of Surgical Oncology, 2019, 26, 714-731.	0.7	9
58	Young Adults With Esophageal Adenocarcinoma Present With More Advanced Stage Tumors and Have Shorter Survival Times. Clinical Gastroenterology and Hepatology, 2019, 17, 1756-1762.	2.4	12
59	Timeline and location of recurrence following successful ablation in Barrett's oesophagus: an international multicentre study. Gut, 2019, 68, 1379-1385.	6.1	73
60	Combined Celiac Ganglia and Plexus Neurolysis Shortens Survival, Without Benefit, vs Plexus Neurolysis Alone. Clinical Gastroenterology and Hepatology, 2019, 17, 728-738.e9.	2.4	49
61	Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma. Journal of Clinical Gastroenterology, 2019, 53, 361-365.	1.1	31
62	Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment. Journal of Biomedical Optics, 2019, 24, 1.	1.4	22
63	Cryotherapy for persistent Barrett's esophagus after radiofrequency ablation: a systematic review and meta-analysis. Gastrointestinal Endoscopy, 2018, 87, 1396-1404.e1.	0.5	56
64	Volumetric laser endomicroscopy interpretation and feature analysis in dysplastic Barrett's esophagus. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1761-1765.	1.4	6
65	Factors Associated With Progression of Barrett's Esophagus: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2018, 16, 1046-1055.e8.	2.4	97
66	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	7.7	396
67	Costs associated with Barrett's esophagus screening in the community: an economic analysis of a prospective randomized controlled trial of sedated versus hospital unsedated versus mobile community unsedated endoscopy. Gastrointestinal Endoscopy, 2018, 87, 88-94.e2.	0.5	35
68	A novel method to prevent catheter dysfunction during sprayÂcryotherapy. Gastrointestinal Endoscopy, 2018, 87, 889-890.	0.5	3
69	Use of volumetric laser endomicroscopy to characterize aÂduodenal neuroendocrine tumor. Gastrointestinal Endoscopy, 2018, 87, 894-895.	0.5	1
70	Increased detection of Barrett's esophagus–associated neoplasia using wide-area trans-epithelial sampling: aÂmulticenter, prospective, randomized trial. Gastrointestinal Endoscopy, 2018, 87, 348-355.	0.5	87
71	Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. Gastroenterology, 2018, 155, 1720-1728.e4.	0.6	67
72	Smokeless Tobacco and Cigar and/or Pipe Are Risk Factors for Barrett Esophagus in Male Patients With Gastroesophageal RefluxÂDisease. Mayo Clinic Proceedings, 2018, 93, 1282-1289.	1.4	7

#	Article	IF	CITATIONS
73	Mucosal Ablation in Patients with Barrett's Esophagus: Fry or Freeze?. Digestive Diseases and Sciences, 2018, 63, 2129-2135.	1.1	12
74	Screening patients for Barrett esophagus: Why, who, and how. Techniques in Gastrointestinal Endoscopy, 2018, 20, 55-61.	0.3	0
75	Response:. Gastrointestinal Endoscopy, 2018, 87, 1595.	0.5	Ο
76	A prospective multicenter study using a new multiband mucosectomy device for endoscopic resection of early neoplasia in Barrett's esophagus. Gastrointestinal Endoscopy, 2018, 88, 647-654.	0.5	15
77	Higher Rate of Barrett's Detection in the First Year After Successful Endoscopic Therapy: Meta-analysis. American Journal of Gastroenterology, 2018, 113, 959-971.	0.2	35
78	Highly Discriminant Methylated DNA Markers for the Non-endoscopic Detection of Barrett's Esophagus. American Journal of Gastroenterology, 2018, 113, 1156-1166.	0.2	58
79	Esophagectomy Outcomes in the Endoscopic Mucosal Resection Era. Annals of Thoracic Surgery, 2017, 103, 890-897.	0.7	5
80	Remote malignant intravascular thrombi: EUS-guided FNA diagnosis and impact on cancer staging. Gastrointestinal Endoscopy, 2017, 86, 150-155.	0.5	25
81	Cytosponge use in risk stratification of Barrett's oesophagus. The Lancet Gastroenterology and Hepatology, 2017, 2, 3-4.	3.7	8
82	Persistence of Nondysplastic Barrett's Esophagus Is Not Protective Against Progression to Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2017, 15, 950-952.	2.4	17
83	Screening and Preventive Strategies in Esophagogastric Cancer. Surgical Oncology Clinics of North America, 2017, 26, 163-178.	0.6	18
84	Cancer diagnostics: Light scattering by pancreatic cysts. Nature Biomedical Engineering, 2017, 1, .	11.6	0
85	Recent Advances in Endoscopy. Gastroenterology, 2017, 153, 364-381.	0.6	17
86	Late Recurrence of Barrett's Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial. Gastroenterology, 2017, 153, 681-688.e2.	0.6	99
87	Predictors of Progression in Barrett's Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry. American Journal of Gastroenterology, 2017, 112, 867-873.	0.2	25
88	Editorial: The Effect of Bias on Estimation of Improved Survival After Diagnosis of Barrett's Esophagus. American Journal of Gastroenterology, 2017, 112, 1265-1266.	0.2	5
89	Radiofrequency Ablation of Barrett's Esophagus. Gastrointestinal Endoscopy Clinics of North America, 2017, 27, 491-501.	0.6	10
90	Breath Testing for Barrett's Esophagus Using Exhaled Volatile Organic Compound Profiling With an Electronic Nose Device. Gastroenterology, 2017, 152, 24-26.	0.6	63

#	Article	IF	CITATIONS
91	Endoscopic Ultrasound Fine-Needle Aspiration Diagnosis of Synchronous Primary Pancreatic Adenocarcinoma and Effects on Staging and Resectability. Clinical Gastroenterology and Hepatology, 2017, 15, 299-302.e4.	2.4	7
92	Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus. Oncotarget, 2017, 8, 203-214.	0.8	53
93	Screening for Barrett's esophagus. Minerva Medica, 2017, 108, 28-42.	0.3	3
94	Diagnosing gastrointestinal illnesses using fecal headspace volatile organic compounds. World Journal of Gastroenterology, 2016, 22, 1639.	1.4	44
95	299 Detection of Barrett's Esophagus by Non-invasive Breath Screening of Exhaled Volatile Organic Compounds Using an Electronic-Nose Device. Gastroenterology, 2016, 150, S67.	0.6	4
96	Emerging Concepts for the Endoscopic Management of Superficial Esophageal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 851-860.	0.9	14
97	Prevalence and Predictors of Gastroesophageal Reflux Complications in Community Subjects. Digestive Diseases and Sciences, 2016, 61, 3221-3228.	1.1	20
98	Computer-aided diagnosis in GI endoscopy: looking into theÂfuture. Gastrointestinal Endoscopy, 2016, 84, 842-844.	0.5	14
99	Pancreatic cyst epithelial denudation: a natural phenomenon inÂthe absence of treatment. Gastrointestinal Endoscopy, 2016, 84, 788-793.	0.5	17
100	MicroRNA Expression Signatures During Malignant Progression From Barrett's Esophagus. Journal of Cellular Biochemistry, 2016, 117, 1288-1295.	1.2	8
101	Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. Gastroenterology, 2016, 150, 599-607.e7.	0.6	144
102	Risk of recurrence of Barrett's esophagus after successful endoscopic therapy. Gastrointestinal Endoscopy, 2016, 83, 1090-1106.e3.	0.5	94
103	Comparative diagnostic performance of volumetric laser endomicroscopy and confocal laser endomicroscopy in the detection of dysplasia associated with Barrett's esophagus. Gastrointestinal Endoscopy, 2016, 83, 880-888.e2.	0.5	110
104	EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses. Gastrointestinal Endoscopy, 2015, 81, 1188-1196.e7.	0.5	30
105	A Randomized Comparative Effectiveness Trial of Novel Endoscopic Techniques and Approaches for Barrett's Esophagus Screening in the Community. American Journal of Gastroenterology, 2015, 110, 148-158.	0.2	92
106	Safety and feasibility of volumetric laser endomicroscopy in patients with Barrett's esophagus (with) Tj ETQc	10 8 9 rgB1	[/Qyerlock]

107	Inter-Observer Agreement among Pathologists Using Wide-Area Transepithelial Sampling With Computer-Assisted Analysis in Patients With Barrett's Esophagus. American Journal of Gastroenterology, 2015, 110, 1257-1260.	0.2	50
108	Impact of celiac neurolysis on survival in patients with pancreatic cancer. Gastrointestinal Endoscopy, 2015, 82, 46-56.e2.	0.5	48

#	Article	IF	CITATIONS
109	Detection of peritoneal carcinomatosis by EUS fine-needle aspiration: impact on staging and resectability (with videos). Gastrointestinal Endoscopy, 2015, 81, 1215-1224.	0.5	28
110	Clinical and Histologic Determinants of Mortality for Patients With Barrett's Esophagus–Related T1 Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2015, 13, 658-664.e3.	2.4	39
111	Screening for Barrett's Esophagus. Gastroenterology, 2015, 148, 912-923.	0.6	54
112	Use of probeâ€based confocal laser endomicroscopy (pCLE) in gastrointestinal applications. A consensus report based on clinical evidence. United European Gastroenterology Journal, 2015, 3, 230-254.	1.6	69
113	Radiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia. Gastroenterology, 2015, 149, 567-576.e3.	0.6	77
114	Immature myeloid progenitors promote disease progression in a mouse model of Barrett's-like metaplasia. Oncotarget, 2015, 6, 32980-33005.	0.8	10
115	Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers. Gastrointestinal Endoscopy, 2014, 80, 984-991.	0.5	25
116	The Efficacy of Screening Colonoscopy. JAMA Internal Medicine, 2014, 174, 483.	2.6	1
117	The Risk of Endoscopic Mucosal Resection in the Setting of Clopidogrel Use. ISRN Gastroenterology, 2014, 2014, 1-5.	1.5	11
118	Risk stratification and surveillance in Barrett oesophagus. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 82-84.	8.2	2
119	Prospective Evaluation of Adverse Events Following Lower Gastrointestinal Tract EUS FNA. American Journal of Gastroenterology, 2014, 109, 676-685.	0.2	27
120	Volumetric Laser Endomicroscopy Detects Subsquamous Barrett's Adenocarcinoma. American Journal of Gastroenterology, 2014, 109, 298-299.	0.2	29
121	Editorial: Shining a New Narrow Band of Light on Old Problems. American Journal of Gastroenterology, 2014, 109, 864-866.	0.2	2
122	Obstructive Sleep Apnea Is a Risk Factor for Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2014, 12, 583-588.e1.	2.4	70
123	Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. Gastrointestinal Endoscopy, 2014, 80, 71-77.	0.5	44
124	Barrett's Esophagus Translational Research Network (BETRNet): The Pivotal Role of Multi-institutional Collaboration in Esophageal Adenocarcinoma Research. Gastroenterology, 2014, 146, 1586-1590.	0.6	5
125	Effects of Autofluorescence Imaging on Detection and Treatment of Early Neoplasia in Patients With Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2014, 12, 774-781.	2.4	39
126	Barrett's Esophagus in 2012: Updates in Pathogenesis, Treatment, and Surveillance. Current Gastroenterology Reports, 2013, 15, 322.	1.1	15

#	Article	IF	CITATIONS
127	Recurrence of Esophageal Intestinal Metaplasia After Endoscopic Mucosal Resection and Radiofrequency Ablation of Barrett's Esophagus: Results From a US Multicenter Consortium. Gastroenterology, 2013, 145, 79-86.e1.	0.6	222
128	The essence of management of Barrett's esophagus. Gastrointestinal Endoscopy, 2013, 78, 702-703.	0.5	0
129	Ablation Is in the Eye of the Beholder. Clinical Gastroenterology and Hepatology, 2013, 11, 643-644.	2.4	1
130	Utility of baseline positron emission tomography with computed tomography for predicting endoscopic resectability and survival outcomes in patients with early esophageal adenocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 975-981.	1.4	10
131	Assessment of the diagnostic performance and interobserver variability of endocytoscopy in Barrett's esophagus: A pilot <i>ex-vivo</i> study. World Journal of Gastroenterology, 2013, 19, 8652.	1.4	13
132	NBI in Barrett esophagus—look more and sample less. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 250-251.	8.2	6
133	Safety of Prior Endoscopic Mucosal Resection in Patients Receiving Radiofrequency Ablation of Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2012, 10, 150-154.	2.4	57
134	Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma. Human Pathology, 2012, 43, 172-179.	1.1	19
135	Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines. Lasers in Surgery and Medicine, 2012, 44, 755-761.	1.1	11
136	Development of Subsquamous High-Grade Dysplasia and Adenocarcinoma After Successful Radiofrequency Ablation of Barrett's Esophagus. Gastroenterology, 2012, 143, 564-566.e1.	0.6	128
137	Endoscopic vs Surgical Resection for Barrett's Intramucosal Adenocarcinoma: Beyond a Therapeutic Equipoise. Gastroenterology, 2012, 143, 257-259.	0.6	2
138	Tissue-Engineered Cell Sheets for Stricture Prevention: A New Connection Between Endoscopy and Regenerative Medicine. Gastroenterology, 2012, 143, 526-529.	0.6	6
139	319 Recurrence of Intestinal Metaplasia After Eradication of Barrett's Esophagus With Radio Frequency Ablation - Results From a BETRNet Consortium. Gastroenterology, 2012, 142, S-73.	0.6	6
140	Tu1120 Obstructive Sleep Apnea is a Risk Factor for Barrett's Esophagus. Gastroenterology, 2012, 142, S-751-S-752.	0.6	3
141	Tu1094 Physician Satisfaction With Current Barrett's Esophagus Surveillance and Acceptability of FISH-Based Testing: A Survey of Gastroenterologists Across the United States. Gastroenterology, 2012, 142, S-744.	0.6	3
142	Medical and endoscopic management of high-grade dysplasia in Barrett's esophagus. Ecological Management and Restoration, 2012, 25, 349-355.	0.2	3
143	Cryotherapy for Persistent Barrett's Dysplasia after Radiofrequency Ablation: If You Can't Burn It, Freeze It!. American Journal of Gastroenterology, 2012, 107, S26-S27.	0.2	2

144 Endoscopic Treatment of Superficial Esophageal Cancers. , 2012, , 340-349.

#	Article	IF	CITATIONS
145	Durability of Radiofrequency Ablation in Barrett's Esophagus With Dysplasia. Gastroenterology, 2011, 141, 460-468.	0.6	432
146	Outcomes of T1b esophageal adenocarcinoma patients. Gastrointestinal Endoscopy, 2011, 74, 1201-1206.	0.5	29
147	Endoscopic Evaluation and Advanced Imaging of Barrett's Esophagus. Gastrointestinal Endoscopy Clinics of North America, 2011, 21, 39-51.	0.6	17
148	Endoscopic Management of Pre-invasive Esophageal Adenocarcinoma. , 2011, , 227-244.		0
149	Endoscopic Treatment for Barrett's Esophagus and Early Esophageal Cancer. Journal of Gastrointestinal Surgery, 2010, 14, 946-947.	0.9	3
150	Endoscopic mucosal resection and endoscopic submucosal dissection in esophageal and gastric cancers. Current Opinion in Gastroenterology, 2010, 26, 1.	1.0	37
151	Combinatorial Chemoprevention Reveals a Novel Smoothened-Independent Role of GLI1 in Esophageal Carcinogenesis. Cancer Research, 2010, 70, 6787-6796.	0.4	42
152	Distinct Role of Kruppel-like Factor 11 in the Regulation of Prostaglandin E2 Biosynthesis. Journal of Biological Chemistry, 2010, 285, 11433-11444.	1.6	37
153	Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointestinal Endoscopy, 2010, 71, 680-685.	0.5	262
154	History, Molecular Mechanisms, and Endoscopic Treatment of Barrett's Esophagus. Gastroenterology, 2010, 138, 854-869.	0.6	181
155	Endoscopic Tri-Modal Imaging Is More Effective Than Standard Endoscopy in Identifying Early-Stage Neoplasia in Barrett's Esophagus. Gastroenterology, 2010, 139, 1106-1114.e1.	0.6	149
156	A novel endoscopic oidrs system for non-invasive early diagnosis of esophageal cancers. , 2009, , .		0
157	Radiofrequency Ablation in Barrett's Esophagus with Dysplasia. New England Journal of Medicine, 2009, 360, 2277-2288.	13.9	1,348
158	A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus. Cancer Research, 2009, 69, 4112-4115.	0.4	202
159	Screening, Surveillance, and Prevention for Esophageal Cancer. Gastroenterology Clinics of North America, 2009, 38, 59-73.	1.0	25
160	Endoscopic and Surgical Treatment of Mucosal (T1a) Esophageal Adenocarcinoma in Barrett's Esophagus. Gastroenterology, 2009, 137, 815-823.	0.6	329
161	Endocytoscopy in Esophageal Cancer. Gastrointestinal Endoscopy Clinics of North America, 2009, 19, 273-281.	0.6	9
162	Preface. Gastrointestinal Endoscopy Clinics of North America, 2009, 19, xiii-xiv.	0.6	1

#	Article	IF	CITATIONS
163	Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. Cancer, 2008, 113, 470-476.	2.0	32
164	Utility of Biomarkers in Prediction of Response to Ablative Therapy in Barrett's Esophagus. Gastroenterology, 2008, 135, 370-379.	0.6	76
165	Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointestinal Endoscopy, 2008, 68, 867-876.	0.5	193
166	A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Human Pathology, 2008, 39, 1128-1135.	1.1	73
167	Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus. American Journal of Gastroenterology, 2008, 103, 788-797.	0.2	1,348
168	Gains and Amplifications of <i>c-myc, EGFR</i> , and <i>20.q13</i> Loci in the No Dysplasia–Dysplasia–Adenocarcinoma Sequence of Barrett's Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1380-1385.	1.1	60
169	Photodynamic therapy for Barrett's esophagus: does light still have a role?. Endoscopy, 2008, 40, 1021-1025.	1.0	28
170	Significance of Neoplastic Involvement of Margins Obtained by Endoscopic Mucosal Resection in Barrett's Esophagus. American Journal of Gastroenterology, 2007, 102, 2380-2386.	0.2	91
171	Long-Term Survival Following Endoscopic and Surgical Treatment of High-Grade Dysplasia in Barrett's Esophagus. Gastroenterology, 2007, 132, 1226-1233.	0.6	271
172	Bone Morphogenetic Protein 4 Expressed in Esophagitis Induces a Columnar Phenotype in Esophageal Squamous Cells. Gastroenterology, 2007, 132, 2412-2421.	0.6	153
173	Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointestinal Endoscopy, 2007, 65, 60-66.	0.5	86
174	Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients (with video). Gastrointestinal Endoscopy, 2007, 65, 185-195.	0.5	292
175	Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointestinal Endoscopy, 2007, 66, 460-468.	0.5	338
176	Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2006, 4, 1221-1224.	2.4	1
177	The Development of a Fluorescence in Situ Hybridization Assay for the Detection of Dysplasia and Adenocarcinoma in Barrett's Esophagus. Journal of Molecular Diagnostics, 2006, 8, 260-267.	1.2	53
178	Frozen Section Analysis of Esophageal Endoscopic Mucosal Resection Specimens in the Real-Time Management of Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2006, 4, 173-178.	2.4	23
179	Endoscopic mucosal resection: Esophageal applications. Current Treatment Options in Gastroenterology, 2005, 8, 41-49.	0.3	5
180	Current strategies in the management of Barrett's esophagus. Current Gastroenterology Reports, 2005, 7, 196-201.	1.1	11

#	Article	IF	CITATIONS
181	Surveillance and screening for Barrett's esophagus: What to do when we have so many patients and so little evidence. ASGE Clinical Update, 2005, 13, 1-4.	0.5	Ο
182	Combined Endoscopic Mucosal Resection and Photodynamic Therapy for High-Grade Dysplasia and Early Cancer in Barrett's Esophagus. Techniques in Gastrointestinal Endoscopy, 2005, 7, 69-72.	0.3	3
183	American Gastroenterological Association Medical Position Statement: Role of the Gastroenterologist in the Management of Esophageal Carcinoma. Gastroenterology, 2005, 128, 1468-1470.	0.6	50
184	American Gastroenterological Association Technical Review on the Role of the Gastroenterologist in the Management of Esophageal Carcinoma. Gastroenterology, 2005, 128, 1471-1505.	0.6	78
185	Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointestinal Endoscopy, 2005, 62, 488-498.	0.5	503
186	How should Barrett?s ulceration be treated?. Surgical Endoscopy and Other Interventional Techniques, 2004, 18, 338-344.	1.3	9
187	Mechanisms of Disease: carcinogenesis in Barrett's esophagus. Nature Reviews Gastroenterology & Hepatology, 2004, 1, 106-112. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago	1.7	47
188	Workshop1 1Members of the workshop composed a group of international experts in BE from gastroenterology, surgery, pathology, molecular biology, outcomes, and epidemiology. Conference chairman: Prateek Sharma; conference moderator: Kenneth McQuaid; group leaders: John Dent, M. Brian Fennerty, Richard Sampliner, Stuart Spechler; participants: Alan Cameron, Douglas Corley, Gary	0.6	579
189	Falk, John Goldblum, John Hunter, Janusz Ja. Gastroenterology, 2004, 127, 310-330. Detection and staging of esophageal cancers. Current Opinion in Gastroenterology, 2004, 20, 381-385.	1.0	10
190	Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clinical Gastroenterology and Hepatology, 2003, 1, 252-257.	2.4	123
191	International, multicenter, partially blinded, randomised study of the efficacy of photodynamic therapy (PDT) using porfimer sodium (POR) for the ablation of high-grade dysplasia (HGD) in barrett's esophagus (BE): Results of 24-month follow-up. Gastroenterology, 2003, 124, A20.	0.6	41
192	EMR for early stage esophageal cancer: setting the stage for improved patient outcomes. Gastrointestinal Endoscopy, 2003, 58, 244-246.	0.5	8
193	Photodynamic therapy in Barrett's esophagus. Gastrointestinal Endoscopy Clinics of North America, 2003, 13, 483-489.	0.6	37
194	Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clinical Gastroenterology and Hepatology, 2003, 1, 252-257.	2.4	108
195	Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clinical Gastroenterology and Hepatology, 2003, 1, 252-7.	2.4	42
196	The Effect of Selective Cyclooxygenase-2 Inhibition in Barrett's Esophagus Epithelium: An In Vitro Study. Journal of the National Cancer Institute, 2002, 94, 422-429.	3.0	115
197	Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology, 2002, 122, 1101-1112.	0.6	334
198	Nonsurgical management of Barrett's esophagus with high-grade dysplasia. Surgical Oncology Clinics of North America, 2002, 11, 321-336.	0.6	25

4

#	Article	IF	CITATIONS
199	Management of Barrett's esophagus with high-grade dysplasia. Surgical Clinics of North America, 2002, 82, 683-695.	0.5	4
200	Role of mucosal ablative therapy in the treatment of the columnar-lined esophagus. Chest Surgery Clinics of North America, 2002, 12, 185-203.	0.8	17
201	Multimodality Therapy for Gastroesophageal Cancers, ,. Journal of Gastrointestinal Surgery, 2002, 6, 527-531.	0.9	1
202	Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology, 2001, 120, 1630-1639.	0.6	419
203	Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointestinal Endoscopy, 2001, 54, 682-688.	0.5	214
204	Mucosal Ablation Therapy of Barrett Esophagus. Mayo Clinic Proceedings, 2001, 76, 433-437.	1.4	15
205	Biomarkers in Barrett Esophagus. Mayo Clinic Proceedings, 2001, 76, 438-446.	1.4	34
206	Biomarkers in Barrett Esophagus. Mayo Clinic Proceedings, 2001, 76, 438-446.	1.4	52
207	Mucosal Ablation Therapy of Barrett Esophagus. Mayo Clinic Proceedings, 2001, 76, 433-437.	1.4	33
208	Photoablation of Barrett's esophagus. Journal of Gastrointestinal Surgery, 2000, 4, 344-345.	0.9	2
209	Complications of Photodynamic Therapy in Gastrointestinal Disease. Gastrointestinal Endoscopy Clinics of North America, 2000, 10, 487-495.	0.6	16
210	Photodynamic Therapy of Barrett's Esophagus. Gastrointestinal Endoscopy Clinics of North America, 2000, 10, 409-419.	0.6	33
211	Endoscopic mucosal resection. Gastrointestinal Endoscopy, 2000, 52, 860-863.	0.5	37
212	Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology, 2000, 119, 624-630.	0.6	135
213	Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointestinal Endoscopy, 2000, 52, 328-332.	0.5	256
214	Current status of photodynamic therapy of Barrett's esophagus. Gastrointestinal Endoscopy, 1999, 49, S20-S23.	0.5	89
215	Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model. Cancer, 1998, 82, 421-427.	2.0	77

216 <title>Laser-induced fluorescence in the detection of esophageal carcinoma</title>., 1995, 2324, 14.

#	Article	IF	CITATIONS
217	Initial results using low-dose photodynamic therapy in the treatment of Barrett's esophagus. Gastrointestinal Endoscopy, 1995, 42, 59-63.	0.5	121